NanoViricides Inc. Denies Rumor That It Is Being Acquired For $4.5B
March 07 2014 - 6:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) denies the
statement made in a blog post on the Seeking Alpha website that it
is being acquired for between $2.25B and $4.5B.
The new article was filed by a “MathewRohlad” in his instablog
on the Seeking Alpha website. He identified himself as an investor
in “undervalued large growth potential stocks."
The article entitled “NanoViricides (NNVC) Acquisition In
Review” claims that an anonymous source informed the author that an
unidentified entity is “intent on acquiring NanoViricides” and that
this phantom entity valued the Company “between 2.5 to 4.5 billion
dollars."
The author has not contacted any of the Company’s executives
prior to this posting, nor has Seeking Alpha attempted to verify
any portion of the story with the Company.
The Company has no knowledge of being an acquisition target, and
has not had any discussions whatsoever of such nature with any
parties. Eugene Seymour, MD, MPH, co-founder and Chief Executive
Officer of NanoViricides, said “We find it odd that Seeking Alpha
would publish one story claiming the Company has no value and a
second claiming that it is about to be acquired for possibly up to
$4.5B.”
The Company provides information regarding its achievements,
major corporate events, as well as business strategy, via its press
releases, the quarterly and annual reports, and other SEC filings
such as the current reports. The Company advises our investors and
shareholders to obtain their information from these authentic
sources, and perform due diligence based on credible and
authoritative sources. The Company further advises our shareholders
and investors that they should not rely on false and baseless
statements from unknown and phantom entities, such as this post, as
well as the prior post by an admitted short seller, both published
on the Seeking Alpha website. The Company has filed an action in
the Supreme Court of the State of New York to compel Seeking Alpha
to disclose the identity of the person who wrote and published a
defamatory, malicious, and libelous article about the Company on
February 11, 2014, on the Seeking Alpha website, as previously
reported.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon,
310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2024 to Oct 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Oct 2023 to Oct 2024